EXTON, Pa., Nov. 10, 2005 (PRIMEZONE) -- ViroPharma Incorporated (Nasdaq:VPHM) today announced that the company will host a conference call and live audio webcast today at 4:30 p.m. to discuss the results of the Phase 1b study with HCV-796, an orally dosed hepatitis C (HCV) viral polymerase inhibitor with the potential to interfere with the replication of HCV, that is being co-developed with Wyeth Pharmaceuticals, a division of Wyeth.
